The U.S. Food and Drug Administration (FDA) on Wednesday approved Merck & Co. Inc.’s MRK Keytruda (pembrolizumab) and ...

Merck says some patents for its top-selling cancer drug, Keytruda, may be extended through 2029.

Merck posted a modest 2026 outlook that fell short of estimates, as it prepares for some drugs to go off patent later this ...

Merck’s fourth quarter was marked by continued demand for its oncology and cardiometabolic franchises, as well as the impact ...

Merck (MRK) ’s stock surged by 41% in the last six months, driven not only by a modest revenue increase but also by a ...

Advocacy groups from 30 countries are urging Merck to create a global access strategy for its once-a-month HIV prevention ...

But now, 13 years after the FDA initially blessed it for skin cancer, the U.S. regulator has approved Keytruda as a second- ...

Merck & Co., Inc. extended Keytruda patent protection to 2029; its 40:30:30 strategy and QLEX migration target 18% total returns. See why MRK stock is a buy.

Merck & Co., Inc. is rated a Buy due to robust asset portfolio, strong shareholder return, and buybacks. Learn more about MRK ...

Merck’s stock falls as the full-year revenue and profit outlooks were below expectations.

Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per ...

There will be a public meeting regarding the closure of the Cherokee Pharmaceuticals hazardous waste facility along the ...